IL31192A - Anti-fibrinolytic bicycloheptane,bicyclooctane and bicyclononane compounds - Google Patents
Anti-fibrinolytic bicycloheptane,bicyclooctane and bicyclononane compoundsInfo
- Publication number
- IL31192A IL31192A IL31192A IL3119268A IL31192A IL 31192 A IL31192 A IL 31192A IL 31192 A IL31192 A IL 31192A IL 3119268 A IL3119268 A IL 3119268A IL 31192 A IL31192 A IL 31192A
- Authority
- IL
- Israel
- Prior art keywords
- acid
- compounds
- ethanol
- added
- bicyclononane
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 22
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 title claims description 4
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical compound C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 title description 2
- 230000001567 anti-fibrinolytic effect Effects 0.000 title 1
- 229940082620 antifibrinolytics Drugs 0.000 title 1
- 239000002253 acid Substances 0.000 claims description 22
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- -1 cyano compound Chemical class 0.000 description 2
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 150000003385 sodium Chemical class 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
and bicyclononane MERCK 29406 This Invention to new compounds capable of counteracting certain hemorrhagic ditions and other disorders resulting from a pathologioal fibrinolytic state in These are bicyclooctane and bicyclononane compounds of the structure II which a is 2 or 3 and each X is either or The invention also relates to pharmaceutical compositions for the prevention or treatmen of a pathological fibrinolytic state i suitable for the oral of from 1 to 20 and preferably 2 to 8 of body weight per day of the above compounds for varying periods of The dissolution of fibrin deposits in mammals is due to their lysis by the enzyme which is formed in the blood from also presen in the conversion plasminogen to is promoted activators in the blood and it appear that excessive fibrinolytic activity results from an abundance of such When too much plasmln is the system of the blood becomes clots cannot be and hemorrhage may situation is known as a fibrinolytic Other enzyme systems the may also be activated in an undesirable manner when such a An Interest has recently developed fibrlnolytio drugs which will inhibit the activation of plasminogen to form These fibrlnolytlc agents are believed to interfere with the tion of the activators of converting plasminogen to The clinical of such drugs include their tion to persons undergoing various kinds of surgery as and prostrate obstetrical hemorrhage and many other uses which have been suggested the literature see Acta Supp volume 1 1966 A standard against which newer ones are generally tested and compared is epsilon known as One deficiency agent has been the very high dosages some cases 3 6 grams or more every 4 to 6 diarrhea side effects such as nausea been two more potent agents have been namely carboxylic acid and acid reported to be more active than by both in vitro and in vivo tests see Anderssen 230 and et al Acta et Toxicol 65 both of which discuss This invention provides a class of aminomethyl acids which shows activities of 5 to 50 times that of in tests essentially the same as those know to correlate with clinical Their use thus constitutes an improved 3 The according to this invention are lic lic acid and the corresponding diketo Further modification of this moleoular such as substitution on the nitrogen or deletion of the between the nitrogen and the appears to destroy the Especially preferred the compound which shows at least 50 times the activity EACA Ln and is 8 times as active vivo in This compound has the further advantage being well absorbed by oral almost as well as when given The compounds of this invention are prepared by catalytic reduction of the corresponding heptane or octane or In the case of the bicycloheptane and bicyclooctane the cyano compound is known and Journal of Organic Chemistry corresponding bicyclononane cyano acid is prepared in a similar synthetic route in which is substituted for ethane in the second syntheses are described in the Plow The keto compounds are similarly prepared except that the keto groups are protected until the end as ethylene ketal The boxylic esters are prepared by direct esterification of the amino acids such as by the use of alcoholic hydrogen chloride or thionyl chloride followed by the alkanoyl amino compounds are prepared by acylation of the amino These esters and alkanoyl derivatives are to be considered as inoludod nf structural formulae and in tho appondod cla SHEET FLOW SHEET Equivalents R ethyl n 2 or 3 Reactions Claisen condensation with Reaction with NaH or other strong base followed by BR Reaction with HS presence of etherate in glacial acetic acid Reduction with Raney nickel Gentle saponification with a base such as NaOH in aqueous alcohol Reaction with triethylamine and chloroformic followed by ammonia to convert the anhydride to the amide Dehydration with in or pyridine Heat with base such as NaOH in aqueous alcohol Catalytic such as over Pt in aqueous alcoholic HCl solution Reaction with glycol in presence of toluene sulfonic acid in benzene Heating with acid The compounds of this invention are used in the method of this invention by either or intravenous although the oral route is The esters and of this class of compounds are not selves very active in but the action of enzymes in vivo may cause the slow liberation of the highly active amino thus providing a prolonged availability of the drug in the This is important because of the tendency of these drugs to be swiftly eliminated in the The compounds of this invention can be used in any pharmaceutically acceptable in the form of tablets or The pharmaceutically acceptable salts of the amino group such as the hydrobromide and of the carboxy group such as the alkali alkaline earth are readily especially in injectable The invention can be illustrated by the ing EXAMPLE 1 acid Hydrochloride salt To a solution of of acid et al JACS 1953 75 in 100 ethanol was added 6 hydrochloric acid and 500 platinum During hydrogenation on a Paar apparatus at room temperature and stopped and the reaction mixture filtered through sintered glass to remove the platinum Evaporation of the colorless filtrate in vacuo left a white solid which was reevaporated with three portions of ethanol to remove most of the excess hydrochloric Purification was accomplished by dissolution in 200 hot ethanol and reprecipitation with 750 absolute ethyl The white in sealed capillary at after air was obtained in Three recrystallizations from ethanol ether gave analytically pure which was dried at over phosphorous pentoxide for 18 hours at The product exhibited a single circular ninhydrin positive spot upon thin layer chromatography on silica gel with acetic Free Amino Acid A sample of analytically pure hydrochloride was dissolved in 2 distilled placed above a column of acetate wet and eluted with distilled Tests with hydrin indicated that all of the free amino acid was tained in the first few of The first 100 of when evaporated in vacuo afforded the free amino After one to three recrystallizations from the material or material dried at for 24 hours melted at with decomposition and some darkening and softening at for 24 hours at over raised the melting point to at EXAMPLE 2 late To 250 of tilled over sodium in a dry atmosphere under nitrogen was added of a dispersion of sodium hydride in mineral oil sodium To this was added in over a with mechanical finely powdered 2 Hydrogen was the mixture became slightly and a pink suspension After removal of 120 of by there was 370 After removal of most of the remaining dimethoxyethane by the mixture was stirred and heated at in an oil bath for 65 The solids were removed by washed with 3 x and diluted with 400 hexane washing with hexane and air drying left Guha Che 1392 Before use in the next synthetic the material was recrystaliized from ethanol and was dried overnight at in dicarbox and was added boron trifluoride The resultant mixture was stirred at room temperature with protection from moisture for three After the tion of 160 the mixture was extracted with 3 x 60 4 x 50 sodium then 3 x After drying over magnesium evaporation of the solven left a viscous Trituration with 70 of methanol and chilling afforded a white tion from then two recrystallizations from gave analytically pure material as Diethyl b A solution in 300 ethanol refluxed with 300 active Raney nickel catalyst for four After removal of the nickel catalyst by the ethanol was removed in vacuo and the product separated from the phase mixture with water by extraction into The combined ether layers were dried over anhydrous magnesium filtered and giving colorless liquid A repeat preparation gave the product in crude Vacuum distillation of crude material afforded colorless Two repeat distillations gave a sample for not removable by the material obtained after one distillation proved of purity sufficient for use in the preparation of ethyl hydrogen hydrogen box To a solution of clean sodium spheres in absolute ethanol was added distilled water and diethyl in one The mixture was stirred magnetically and refluxed for 20 hours under After removal of most of the ethanol in vacuo from the water was added to the Unsaponified diester was removed by extraction into 3 x 25 and ester was covered after drying and removal of the of the chilled aqueous layer with 8 N chloric acid gave a white which was extracted into 4 x 50 ethyl The combined ethyl acetate after afforded viscous solution in 100 chloroform and chilling enabled removal of unwanted the separation could not be cleanly and completely achieved in this as monitored by TLC Evaporation of the filtrate and chromatography over silica gel using form as the gave the mono acid while the diacid did not elute from the There was recovered a slightly oily solid which appeared homogenous by from hexane gave material Ethyl carbox In a dry nitrogen ethyl hydrogen late was dissolved in 60 dry A After cooling to was then over a 10 minute period ethyl chloro in 10 chloroform with keeping the temperature between and After stirring for an additional 15 minutes at ammonia gas was bubbled through the stirred mixture for 15 minutes with continued The was removed and the suspension allowed to stir for 17 hours After a thorough washing with N hydrochloric saturated sodium water and drying over magnesium removal of the chloroform in vacuo left a white which was shown to be homogenous by thin layer yield Three recrystallizations of a small sample from gave an analytical sample Ethyl To dissolved in 30 freshly distilled A molecular was added phosphorous The mixture was refluxed for 20 minutes with protection from moisture After removal of most of the excess solvent and phosphorous oxychloride by distillation in vacuo the red liquid residue was treated with cold saturated sodium evaporation of the pentane layer afforded a pale yellow The material was to be homogenous by thin layer possessed the expected absorptions in the infrared was saponified directly to the corresponding cyano acid without further ox acid To dissolved in 20 absolute ethanol added of sodium The mixture was refluxed for 2 then stirred night at After removal of the ethanol in the remaining solid was dissolved in 20 extracted with then acidified with hydrochloric acid and the product extracted into After washing and drying over magnesium removal of the ether afforded 790 white crude The material was shown to be homogeneous by thin layer The upon recrystallization from remained unchanged in melting and found to trap large quantities of solvent removed only on drying in vacuo at A small sample was recrystallized three times from benzene and after drying for analysis melted at acid hydrochloride To a solution of acid in 40 absolute ethanol was added 20 distilled 35 for 2 After removal of the catalyst by the filtrate was stripped in vacuo at then reevaporated several times with fresh portions of distilled A white solid in nearly quantitative Thin layer chromatography indicated one ninhydrin positive One recrystallization from afforded the pure 371 The sample was recrystallized three more times from et ether for without change in melting EXAMPLE 1 was prepared from the ing dioxo compound essentially as described by Holtz and 8δ To a solution of 2 in 9CC ethanol was added of N The mixture was stirred magnetically and refluxed under nitrogen for 22 After removal of most of the ethanol in 250 water was added and the mixture extracted with ethyl acetate for recovery of of the starting diester which could be The chilled aqueous layer was acidified with 30 of then extracted several times with ethyl The combined in affording of white which was shown by thin layer chromatography to be a mixture of the desired mono acid with diacid of and respectively in silica employing acetic acid as the Passage of this material through a column of 500 of silica employing chloroform and chloroform ethyl acetate as the eluant enabled clean separation of the mono and of the crude mono acid from the column from benzene afforded the pure in yield based upon unrecovered Several recrystallizations from ethanol gave an analytical To a solution of ethyl dicarboxylate in 500 dry chloroform was added triethyla ine To the chilled solution was added ethyl chloroformate over a maintaining the temperature at After the addition was stirring was continued at this temperature for an additional thirty With continued cooling in an ammonia gas was bubbled into the mixture for the mixture allowed to warm to room temperature with stirring After removal of the chloroform in addition of water and thorough extraction with ethyl acetate afforded nearly analytically pure amide 159 Three To a solution of of in 170 dry pyridine was added slowly 17 phosphorous ox The resulting solution was heated at for about 1 The volume was duced to about 30 by distillation in vacuo and the cooled residue added cautiously to about 300 saturated sodium bicarbonate containing Extraction with ethyl drying over magnesium filtering and stripping in vacuo left a yellow oil which solidified when from hexane afforded pure yield tion from hexane gave an analytical acid To dissolved in 50 ethanol was added sodium The mixture was refluxed for 6 hours under then left After removal of the ethanol in vacuo and the addition of starting material was recovered by ether Careful acidification of the cold aqueous layer produced an oil which quickly began to The product was collected either by filtration or extraction into ethyl After one recrystallization of the crude cyano acid based on unrecovered of pure product was Recrystallization from carboxylic acid To 590 mg aoid in 40 ml ethanol was added ml of hydrochloric acid and 100 mg platinium The compound was hydrogenated for 2 hours at filtered and then fluxed for 8 hours with 20 ml 6 hydrochloric After evaporation in vacuo and several times with small portions of the crude amino hydrochloride was dissolved in 5 water and through a column of acetate Evaporation of the effluent gave the crystalline Several reorystallizations from gave the amino acid for analysis The material appears to darken upon heating above exhibits the expected infrared absorptions 1610 1560 1450 1380 1270 1210 1140 780 560 350 and appears homogeneous upon thin layer chromatography on silica gel with butanolacetic It will be observed that the diketo compounds of 3 have been identified as having and configurations due to a lack of a plane of their mirror images are not EXAMPLE acid The above compound was prepared according to the cedure reported by Wilcox et al Journal of Organic Chemistry page 18 acid hydrochloride To 165 mg of acid dissolved in 20 ml ethanol was added 8 ml of ml of hydrochloric acid and 100 mg platinum The compound was hydrogenated on a Parr at 35 at room temperature for one After removal of the catalyst by filtration through sintered the filtrate was evaporated in vacuo at steam bath It was then washed three times with fresh 10 ml portions of A white solid 185 with an with The material appeared to be homogeneous by thin layer chromatography silica gel with Three from gave an analytical with EXAMPLE 5 Compounds are tested by measuring the effect of the inhibitor at various concentrations on the lyeie times of a fibrin clot with a constant concentration of streptokinase in The concentration of the inhibitor which increases the geometric mean lysis time by is Epsilon amino caproic acid is used as a standard and the relative potencies are with the following results 19 Compound Relative vitro Activity Reference Compound EACA Compounda acid acid lic acid aoid hydrochloride a y 30 Ihe Gomplimenls REINHOLD COHN AND PARTNERS PATENT ATTORNEYS 0 D 3 20 insufficientOCRQuality
Claims (1)
1. CLAIMS bicyclooctane and bicyclononane compounds the formula X X wherein each X stands for two hydrogen atoms or one oxygen atom and n is 2 or and their pharmaceutically acceptable acid and its acid and its carboxylic acid and it3 A process of preparing compounds of formula I in Claim which comprises catalytic reduction of a compound of the structure 21 Υ II which Y is or 0 and n is 2 or when Y is not heating with a mineral acid to free the Pharmaceutical comprising as an active agent a compound according to any of Claims 1 to For the Applicants AND PARTNERS insufficientOCRQuality
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69040467A | 1967-12-14 | 1967-12-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL31192A0 IL31192A0 (en) | 1969-02-27 |
| IL31192A true IL31192A (en) | 1972-03-28 |
Family
ID=24772307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL31192A IL31192A (en) | 1967-12-14 | 1968-12-01 | Anti-fibrinolytic bicycloheptane,bicyclooctane and bicyclononane compounds |
Country Status (16)
| Country | Link |
|---|---|
| AT (1) | AT289752B (en) |
| BE (1) | BE725459A (en) |
| BR (1) | BR6804856D0 (en) |
| CH (1) | CH518262A (en) |
| DE (1) | DE1812979A1 (en) |
| DK (1) | DK122809B (en) |
| ES (1) | ES361113A1 (en) |
| FI (1) | FI50970C (en) |
| FR (2) | FR8218M (en) |
| GB (1) | GB1209799A (en) |
| IE (1) | IE32928B1 (en) |
| IL (1) | IL31192A (en) |
| NL (1) | NL6817950A (en) |
| NO (1) | NO125182B (en) |
| SE (1) | SE357196B (en) |
| YU (2) | YU33008B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3641128A (en) * | 1969-06-17 | 1972-02-08 | Merck & Co Inc | Antifibrinolytic compounds |
| JPS4910951B1 (en) * | 1970-03-25 | 1974-03-13 | ||
| IE47589B1 (en) * | 1978-01-20 | 1984-05-02 | Daiichi Seiyaku Co | Process for producing 4-amino-methylbicyclo (2,2,2)octane-1-carboxylic acid and intermediate compound therefor |
| DE3336678A1 (en) * | 1983-10-08 | 1985-04-25 | Rudolf Wanzl Kg, 8874 Leipheim | Stackable shopping trolley with brake device |
| DE19917999B4 (en) * | 1999-04-21 | 2007-01-11 | Brand Gülletechnik GmbH | Automatically releasing brake device for a mobile transport device |
-
1968
- 1968-12-01 IL IL31192A patent/IL31192A/en unknown
- 1968-12-02 YU YU2827/68A patent/YU33008B/en unknown
- 1968-12-02 IE IE1465/68A patent/IE32928B1/en unknown
- 1968-12-04 SE SE16572/68A patent/SE357196B/xx unknown
- 1968-12-05 DE DE19681812979 patent/DE1812979A1/en not_active Withdrawn
- 1968-12-05 ES ES361113A patent/ES361113A1/en not_active Expired
- 1968-12-09 GB GB58306/68A patent/GB1209799A/en not_active Expired
- 1968-12-09 FI FI683518A patent/FI50970C/en active
- 1968-12-13 BE BE725459D patent/BE725459A/xx unknown
- 1968-12-13 BR BR204856/68A patent/BR6804856D0/en unknown
- 1968-12-13 DK DK611768AA patent/DK122809B/en not_active IP Right Cessation
- 1968-12-13 FR FR178115A patent/FR8218M/fr not_active Expired
- 1968-12-13 FR FR178116A patent/FR1605239A/fr not_active Expired
- 1968-12-13 AT AT1216768A patent/AT289752B/en not_active IP Right Cessation
- 1968-12-13 NL NL6817950A patent/NL6817950A/xx unknown
- 1968-12-13 NO NO4991/68A patent/NO125182B/no unknown
- 1968-12-13 CH CH1867168A patent/CH518262A/en not_active IP Right Cessation
-
1973
- 1973-08-23 YU YU2271/73A patent/YU34393B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI50970B (en) | 1976-05-31 |
| GB1209799A (en) | 1970-10-21 |
| NL6817950A (en) | 1969-06-17 |
| YU33008B (en) | 1976-03-31 |
| IE32928L (en) | 1969-06-14 |
| BE725459A (en) | 1969-06-13 |
| SE357196B (en) | 1973-06-18 |
| FI50970C (en) | 1976-09-10 |
| YU282768A (en) | 1975-08-31 |
| CH518262A (en) | 1972-01-31 |
| IL31192A0 (en) | 1969-02-27 |
| DE1812979A1 (en) | 1969-07-24 |
| IE32928B1 (en) | 1974-01-23 |
| YU34393B (en) | 1979-07-10 |
| FR1605239A (en) | 1973-08-31 |
| AT289752B (en) | 1971-05-10 |
| ES361113A1 (en) | 1970-08-01 |
| DK122809B (en) | 1972-04-17 |
| NO125182B (en) | 1972-07-31 |
| BR6804856D0 (en) | 1973-03-20 |
| YU227173A (en) | 1978-12-31 |
| FR8218M (en) | 1970-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5420155A (en) | Tetramic acid derivatives | |
| Martin | Preparation of saturated and unsaturated symmetrical monoglycerides | |
| US3704233A (en) | O-acyl-lysergols and process for preparing them | |
| JPH08501057A (en) | Novel anticoagulant factor peptide derivative, pharmaceutical composition containing the same, and method for producing the same | |
| KR880001466B1 (en) | Process for preparing pyridyl compounds | |
| IL31192A (en) | Anti-fibrinolytic bicycloheptane,bicyclooctane and bicyclononane compounds | |
| US3763218A (en) | Esters of phenylalanine | |
| US3517055A (en) | Anti-fibrinolytic agent | |
| US3551576A (en) | Anti-fibrinolytic agent | |
| US3634499A (en) | Antifibrinolytic compounds | |
| US3517057A (en) | Preparation of optically active amino acids | |
| JPH0358973A (en) | N,n'-bis(alkoxyalkyl)-pyridine-2,4- dicarboxylic acid diamides | |
| US3720775A (en) | Treatment of a pathological fibrinolytic state in patients | |
| SK280738B6 (en) | Arylalkyl esters of 4,5-dihydroxy-9,10-dihydro-9,10-dioxo-2- anthracenecarboxylic acid, process for their preparation, pharmaceuticals them containing, and their use | |
| US3641128A (en) | Antifibrinolytic compounds | |
| US3723514A (en) | (-)threo-3-(4-hydroxy-3-methoxyphenyl)-serine | |
| US4348328A (en) | 25-Substituted-5α-cholestane-3β,22S-diol | |
| US4009283A (en) | Antiinflammatory and antithrombotic compositions and method of use | |
| US3766245A (en) | 3,5-dialkoxyalkoxy-4-substituted benzoic acid esters | |
| DE2029807C3 (en) | 4-Aminomethylbicyclo- [2.2.2] -octyl- (l) -acetic acid and its physiologically acceptable salts, processes for their preparation and their use | |
| US4404205A (en) | 2-Oxo-2,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepines and antianginal method of use thereof and of 4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepines | |
| US4252812A (en) | 2-Substituted-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles | |
| CA1328076C (en) | Cerebral hyperkinemic composition containing a dihydropyridine derivative | |
| JP2672311B2 (en) | Anticholinergic compound and pharmaceutical composition containing this compound | |
| US3577409A (en) | 2-rch2nh-4-x-5-sulfamylbenzoic acids |